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Abstract
Purpose To determine the associations between lysosomal-associated transmembrane protein 4b (LAPTM4B) gene copy 
number and response to different chemotherapy regimens in hormone receptor negative (HR-) primary breast carcinomas.
Patients and methods Two cohorts were analyzed: (1) 69 core biopsies from HR-breast carcinomas treated with neoadju-
vant chemotherapy (anthracycline based in 72.5% of patients and non-anthracycline based in 27.5% of patients). (2) Tissue 
microarray (TMA) of 74 HR-breast carcinomas treated with adjuvant therapy (77.0% of the patients received anthracycline, 
17.6% of the patients non-anthracycline-based therapy, and in 5.4% of the cases, no treatment data are available). Interphase 
FISH technique was applied on pretreatment core biopsies (cohort I) and on TMAs (cohort II) using custom-made dual-
labelled FISH probes (LAPTM4B/CEN8q FISH probe Abnova Corp.).
Results In the neoadjuvant cohort in the anthracycline-treated group, we observed a significant difference (p = 0.029) of 
average LAPTM4B copy number between the non-responder and pathological complete responder groups (4.1 ± 1.1 vs. 
2.6 ± 0.1). In the adjuvant setting, the anthracycline-treated group of metastatic breast carcinomas was characterized by higher 
LAPTM4B copy number comparing to the non-metastatic ones (p = 0.046). In contrast, in the non-anthracycline-treated group 
of patients, we did not find any LAPTM4B gene copy number differences between responder vs. non-responder groups or 
between metastatic vs. non-metastatic groups.
Conclusion Our results confirm the possible role of the LAPTM4B gene in anthracycline resistance in HR− breast cancer. 
Analyzing LAPTM4B copy number pattern may support future treatment decision.
Keywords Breast carcinomas · LAPTM4B · Anthracycline-based chemotherapy · FISH
Introduction
In the 1990s, chemotherapy regimens containing anthracy-
clines largely replaced the previous regimen of cyclophos-
phamide, methotrexate, and 5-fluorouracyl (CMF) for the 
treatment of breast cancer. Subsequently, anthracyclines 
(doxorubicin and epirubicin) became the most widely used 
chemotherapeutic agents for breast cancer given as either 
adjuvant or neoadjuvant therapy [1, 2]. However, in the era 
of personalized therapy, clinical decision could be signifi-
cantly optimized by a robust and reliable biomarker predict-
ing response to this therapy.
Several potential response predictors for anthracyclines, 
such as increased topoisomerase-II-alpha levels, were pro-
posed, but none of those has reached or passed the stage of 
large-scale independent clinical validation with the desired 
predictive potential [3, 4].
Using an integrative genomics approach, Li et al. [5] 
identified a functionally validated predictor of anthracycline 
treatment efficacy. Amplification of chromosomal region 
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8q22 was significantly associated with treatment resist-
ance. Expression levels of one of the genes contained in 
that region, the lysosomal-associated transmembrane protein 
4b (LAPTM4B), could be linked to altering the intracellular 
distribution of anthracycline in experimental circumstances. 
Anthracyclines likely enter the cells via simple diffusion [6], 
where they bind to proteasomes and by an ATP-dependent 
nuclear pore-mediated mechanism get transported into 
the nuclei [7]. Both doxorubicin and epirubicin are weak 
bases; they can accumulate in acidic intracellular compart-
ments, such as the lysosomes. Several studies reported that 
resistant cancer cells are able to accumulate significantly 
more anthracyclines in cytoplasmic organelles, resulting in 
reduced nuclear drug accumulation and decreased cytotox-
icity [8], but the potential molecular regulation of the drug 
sequestration in acid lysosomes has been unclear. In the 
previous experiments, the knockdown of LAPTM4B sig-
nificantly decreased the ability of lysosomes to retain doxo-
rubicin [5]. According to other results, the preservation of 
lysosome membrane integrity by LAPTM4B also prevents 
cathepsin release and the following caspase-mediated apop-
tosis, which was detectable after doxorubicin but not taxol 
exposure [9].
In the current study, we investigated whether we could 
potentially convert the initial observations of Li et al. [5] 
into a diagnostic test that is widely available in the diagnos-
tic setting: FISH-based copy number analysis. To achieve 
this, first, we needed to determine whether the LAPTM4B/
CEN8q ratio or the average copy number of LAPTM4B/
cell was more robustly informative of treatment response. 
The ultimate aim of the study was to determine whether 
the presence of extra copy of LAPTM4B gene had negative 
predictive value to anthracycline-based treatment in patients 
with hormone receptor negative (HR−) breast carcinomas.
Patients and methods
Study population
A total of 143 HR− breast carcinoma cases were enrolled in 
this study and were analyzed in two different cohorts. The 
study was ethically approved by the Semmelweis University 
Institutional Review Board (SE-TUKEB 120/2013).
The first cohort included 69 core biopsies of HR− (64 
TNBC and 5 HER2+) primary breast carcinoma cases diag-
nosed between 2004 and 2016, who received at least two 
cycles of neoadjuvant chemotherapy, and then underwent 
surgery. Patients were eligible for neoadjuvant therapy if 
they had histologically confirmed invasive breast cancer and 
imaging examinations ruled out distant metastases.
Fifty out of sixty-nine (72.5%) patients were treated with 
anthracycline-based neoadjuvant chemotherapy (mainly in 
combination with taxane), whereas 19 patients (27.5%) rep-
resented the control arm receiving non-anthracycline-based 
(mostly platinum in combination with taxane) chemother-
apy. The clinicopathological data are presented in Table 1. 
The detailed treatment data are presented in supplementary 
Table 1.
The degree of response to therapy was categorized fol-
lowing Pinder et al. [10]. Complete pathological response 
(pCR) either (1) no residual carcinoma in breast and lymph 
nodes or (2) no residual invasive tumor, but DCIS present 
in breast and the absence of any residual invasive tumor in 
the lymph nodes. Partial response to therapy (pPR) either 
(1) minimal residual disease⁄near total effect (e.g., < 10% of 
tumor remaining) or (2) evidence of response to therapy but 
with 10–50% of tumor remaining or (3) > 50% of tumor cel-
lularity remains evident, when compared with the previous 
core biopsy sample, although some features of response to 
therapy present. No evidence of response to therapy (pNR).
The second cohort included 74 formalin-fixed paraf-
fin-embedded (FFPE) samples of surgically removed 
HR− breast carcinomas (39 TNBC, 27 HER2+, and 8 with 
no reliable HER2 data). Patients in this cohort were treated 
Table 1  Clinicopathological characteristics of the study group treated 
with neoadjuvant chemotherapy
Parameter No. of patients (N = 69)
Mean age (years) 50 (range: 26–79)
IHC-based molecular types
 TNBC 64 (92.8%)
 HR−, HER2+ 5 (7.2%)
Clinical tumor stage
 Primary tumor
  T1 2 (2.9%)
  T2 42 (60.9%)
  T3 12 (17.4%)
  T4 13 (18.8%)
 Regional lymph node
  N0 25 (36.2%)
  N1 19 (27.5%)
  N2 19 (27.5%)
  N3 6 (8.8%)
Therapy
 Anthracycline-based 50 (72.5%)
 Non-anthracycline-based 19 (27.5%)
Pathological response to neoadjuvant therapy
 pCR 26 (37.7%)
 pPR 38 (55.1%)
  pPRi 6 (15.78%)
  pPRii 13 (34.21%)
  pPRiii 19 (50%)
 pNR 5 (7.2%)
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with chemotherapy in adjuvant setting between 1999 and 
2006. Of these patients, 57/74 (77.0%) received anthra-
cycline-based (22.8% in combination with taxane) and 
13/74 (17.6%) received non-anthracycline-based therapies 
(as control arm), mainly CMF regimens. In 4/74 (5.4%) 
cases, no reliable treatment data were available. The clin-
icopathological data are presented in Table 2. The detailed 
treatment data are presented in supplementary Table 2. 
In the adjuvant cohort, distant metastasis-free survival 
(DMFS) was assessed and defined as the time elapsed 
between the first diagnosis of primary breast carcinoma 
and the date of appearance of any distant metastasis. The 
occurrence or absence of distant metastasis was considered 
as an indirect surrogate marker for response to different 
chemotherapy regimens.
Follow-up data collection for both cohorts ended in 
December 2016.
Evaluation of LAPTM4B copy number using FISH 
technique
Interphase FISH analysis was used to evaluate the copy 
number status of LAPTM4B gene.
5 µm-thick FFPE tissue sections were mounted onto 
Superfrost Plus positively charged slides, and deparaffinized 
and rehydrated in distilled water. For antigen retrieval, sec-
tions were incubated in citric acid-based antigen unmasking 
solution (Vector Laboratories, Inc. Burlingame, CA, USA) 
at 95 °C for 20 min. Cell lysis was established by incubating 
the sections in Triton X-100 (AppliChem GmbH, Ottoweg 
4, 64291 Darmstadt, Germany) –SSC solution at 65 °C for 
30 min. Sections were then subjected to digestion in pep-
sin solution, for 12 min at 37 °C, and then washed twice 
in SSC for 5 min.  ZytoLight® FISH-Tissue Implementation 
Kit (ZytoVision GmbH, Bremerhaven, Germany) was used 
in prehybridizational steps. Sections were air-dried prior to 
denaturation at 73 °C for 10 min. Hybridization was per-
formed using 4 µl of custom-made, Texas Red/FITC dual-
labelled LAPTM4B/CEN8q FISH probes (Abnova Corp., 
Taoyuan City, Taiwan) per slide at 37 °C for 16–18 h in 
an automated hybridization chamber (ZYTOMED Systems 
GmbH Berlin, Germany). Slides were then immersed in 
wash buffer SSC for 30 min at 45 °C, rinsed in water for 
10 min, air-dried. Cell nuclei were counterstained with DAPI 
in antifade solution (Vector Laboratories, Inc. Burlingame, 
CA, 94010, USA).
The Leica DM RXA fluorescent microscope equipped 
with Leica DFC 365FX high-performance CCD camera 
(Leica Microsystems GmbH, Wetzlar, Germany) and with 
DAPI long-pass, FITC, and Texas Red filters was used to 
evaluate the hybridization results.
Areas with well-separated cell nuclei and overall good 
hybridization signals were selected for analysis. Minimum 
two FISH images per case were digitally captured at 63x 
magnification. For each case, red (LAPTM4B) and green 
(CEN8 centromeric region) fluorescent signals were counted 
separately in at least 50 non-overlapping interphase nuclei. 
Based on these data, the following parameters were cal-
culated: average LAPTM4B copy number/cell, average 
CEN8q copy number/cell, LAPTM4B/CEN8q ratio, average 
LAPTM4B copy number/cell in amplified cell population, 
and percentage of polysomic or amplified cells.
Statistical analysis
SPSS 23.0 (SPSS Inc., Chicago, IL, USA) was used for 
statistical analysis. The Shapiro–Wilk test was applied to 
control the normality of data, and Leven’s test was used to 
control the equality of variances. Non-parametric tests were 
applied for statistical analyses. Receiver-operating character-
istic (ROC) curve analysis was used to determine the optimal 
Table 2  Clinicopathological characteristics of the study group treated 
with adjuvant chemotherapy
Parameter No. of patients (N = 74)
Mean age (year) 52 (range: 32–81)
IHC-based molecular types
 TNBC 39 (52.7%)
 HR−, HER2+ 27 (36.5%)
 HR−, HER2 n.a. 8 (10.8%)
Pathologic tumor stage
 Primary tumor
  pT1 19 (25.6%)
  pT2 37 (50.0%)
  pT3 9 (12.2%)
  pT4 5 (6.8%)
  Unknown 4 (5.4%)
 Regional lymph node
  pN0 19 (25.6%)
  pN1 21 (28.4%)
  pN2 17 (23.0%)
  pN3 4 (5.4%)
  Unknown 13 (17.6%)
Distant metastases
 Yes 30 (40.5%)
 No 44 (59.5%)
Therapy
 Anthracycline-based 57 (77.0%)
 Non-anthracycline-based 13 (17.6%)
 Unknown 4 (5.4%)
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cut-off value of LAPTM4B copy number used in survival 
tests. Fisher’s exact, Kruskal–Wallis, and Mann–Whit-
ney–Wilcoxon tests were used to compare the LAPTM4B 
copy number to the clinical-pathological data of the primary 
tumors, including therapy response in neoadjuvant cohort 
and distant metastasis formation in adjuvant cohort as end 
point. The Kaplan–Meier, log-rank, and Cox regression tests 
were used for survival analysis (DMFS—distant metastasis-
free survival). The Cox model included the known breast 
carcinoma prognostic factors such as age at the initial diag-
nosis, pT, and pN status beside LAPTM4B copy number 
category. A p value of less than 0.05 was considered statisti-
cally significant.
Results
In the first cohort, the mean age of patients was 50 years 
(range: 26–79 years); all cases had invasive carcinoma of no 
special type. Based on the subtypes, 64/69 (92.8%) TNBC 
and 5/69 HER2+ (7.2%) cases were analyzed. After neoad-
juvant therapy, pCR was achieved in 26 cases (37.7%), pPR 
in 38 cases (55.1%), and pNR in 5 cases (7.2%) (Table 1 
and Suppl. Table 1). The average LAPTM4B/CEN8q ratio 
was ≥ 2.0 in only 6/69 (8.6%) cases with the highest ratio 
being 3.71.
Considering the average LAPTM4B copy number/cell in 
the group of patients receiving anthracycline-based neoad-
juvant therapy, higher average LAPTM4B gene copy number 
was observed in the pNR group compared to pCR group 
(4.1 ± 1.1 vs. 2.6 ± 0.1, p = 0.029) (Figs. 1a, b, 2a).
We also compared average LAPTM4B gene copy num-
bers between patients who had no regression or who pre-
sented minimal response to anthracycline-based neoadjuvant 
therapy (> 50% residual tumor remaining) (pNR + pPRiii) 
versus cases with pCR. Again, significantly higher average 
gene copy number was found in the group of patients with 
inferior response to anthracycline-based neoadjuvant therapy 
(3.3 ± 0.3 vs. 2.6 ± 0.1, p = 0.035, Fig. 2c).
The same is true for average CEN8q being significantly 
higher in the pNR and pNR + pPRiii groups compared to 
pCR group (3.7 ± 0.9 vs. 2.2 ± 0.1, p = 0.048 and 2.9 ± 0.3 
vs. 2.2 ± 0.1, p = 0.040 respectively).
In the non-anthracycline-treated group of patients, we 
observed pNR in a single case (Fig. 2b). Therefore, we com-
pared LAPTM4B gene copy number between pNR + pPRiii 
and pCR groups, resulting no significant differences 
(p = 0.360) (Fig. 2d).
Regarding average CEN8q copies, in the non-anthracy-
cline-treated group of patients, no significant differences 
were observed between pNR + pPRiii and pCR groups 
(p = 0.879).
In the second cohort, the mean age of the patients was 
52 years (32–81). Of the 74 analyzed cases, 94.6% had inva-
sive carcinoma of no special type and 5.4% of the cases 
presented other histological type (n = 1 invasive lobular 
carcinoma, n = 1 carcinoma anaplasticum, n = 1 carcinoma 
medullare, n = 1 apocrin carcinoma). By considering the 
breast carcinoma subtypes, 39/74 (52.7%) were TNBC, 
Fig. 1  LAPTM4B FISH images 
in anthracycline-treated cases. 
a Normal LAPTM4B copy 
number in a core biopsy case 
diagnosed with pCR after 
neoadjuvant therapy and b 
higher average LAPTM4B gene 
copy number in a case without 
any therapy response after neo-
adjuvant therapy; c a primary 
breast carcinoma case treated 
with adjuvant chemotherapy 
and presenting no distant organ 
metastasis during the follow-up 
period (d) and a primary breast 
carcinoma case who had higher 
average LAPTM4B gene copies 
and recurrence in distant organs. 
LAPTM4B gene was labelled 
with red, whereas chromo-
some 8 centromeric region was 
stained with green fluorescent 
dye. Cell nuclei were counter-
stained with DAPI (blue). FISH 
photos were acquired using 63× 
objective
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27/74 (36.5%) HER2 +, and in 8/74 (10.8%) cases, the HER2 
status was unknown. During the follow-up period, distant 
metastases occurred in 30 (40.5%) cases (Table 2 and Suppl. 
Table 2). LAPTM4B/CEN8q ratio ≥ 2.0 was observed in only 
4/74 (5.4%) cases. Again considering the average LAPTM4B 
gene copy number in the adjuvant anthracycline-treated 
Fig. 2  Association between average LAPTM4B copy number and 
therapy response in the neoadjuvant (a–d) and in the adjuvant cohort 
(e, f). a In the anthracycline-treated cohort, significantly higher 
average LAPTM4B gene copy number was observed in pNR group 
compared to pCR group (p = 0.029). b In the non-anthracycline-
treated group of patients, we observed pNR in a single case. c Sig-
nificantly higher average LAPTM4B gene copy number observed 
in pNR + pPRiii group compared to pCR group (p = 0.035) in the 
anthracycline-treated cohort, whereas, in the non-anthracycline-
treated cohort, (d) no significant differences were observed between 
the two groups. e Average gene copy number was significantly higher 
in metastatic cases, comparing to the non-metastatic ones in anthra-
cycline-treated cohort (p = 0.046) and no significant differences in the 
non-anthracycline-treated cohort (f). A p ≤ 0.050 was considered sta-
tistically significant using two-sided Mann–Whitney–Wilcoxon exact 
test
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patient cohort, the average LAPTM4B gene copy number 
was higher in metastatic cases, compared to the non-met-
astatic ones (2.2 ± 0.2 vs. 1.9 ± 0.1, p = 0.046, Figs. 1c, d, 
2e). In patients treated with other than anthracycline chemo-
therapy, no significant differences were detected between 
metastatic vs. non-metastatic groups (Fig. 2f).
Regarding average CEN8q copies, no significant differ-
ences were observed between metastatic vs. non-metastatic 
groups neither in anthracycline-treated nor in non-anthracy-
cline-treated patients.
Comparison of the two HR− subtypes (HER2+ and 
TNBC cases) showed no significant differences in the aver-
age LAPTM4B gene copy number/cell (p = 0.328).
Kaplan–Meier curve estimation based on DMFS revealed 
that higher LAPTM4B copy number was an independent 
predictor for DMFS in the anthracycline-treated adjuvant 
cohort (Log-rank test, p = 0.037). Cut-off value for poor 
prognosis was defined as follows: the ratio of amplified cell 
(LAPTM4B/CEN8q ≥ 2.0) population is more than 15% and 
the average gene copy number is more than 2.5 per sample 
(Fig. 3). Based on these criteria, of the 22/57 patients treated 
with anthracycline-based adjuvant chemotherapy and diag-
nosed with distant metastases, 6/22 cases presented higher 
LAPTM4B gene copy number, whereas, in 16/22 cases, 
lower LAPTM4B gene copy number was detected. Cox 
regression analysis was also performed, revealing associa-
tion between increased LAPTM4B gene copy number and 
DMFS (p = 0.044).
Discussion
Anthracyclines are still the most widely used chemother-
apeutic agents given as either adjuvant or neoadjuvant 
therapy [11, 12]. Considering that approximately 30% of 
the early stage breast cancers progress to the metastatic 
stage, and the fact that the response rate to anthracycline 
or taxane-based chemotherapy ranges from 30 to 70%, pre-
dictors of treatment efficacy to the various chemothera-
peutic agents would have significant clinical importance 
[1, 3, 13, 14].
The potential role of LAPTM4B in tumor progression 
and chemotherapy resistance was first recognized about 
a decade ago. Kasper et al. [15] by analyzing different 
tumor types found that LAPTM4B was upregulated in 
88% (23/26) of lung, in 67% (18/27) of colon carcinoma 
patients, and in the majority of endometrial (30/44), breast 
(27/53) and ovarian (11/16) carcinomas. They concluded 
that LAPTM4B have a dual functional involvement in 
tumor cell proliferation as well as in multidrug-resist-
ance. Later, a significant functional association was found 
between lysosomal LAPTM4B overexpression and poor 
response to anthracycline chemotherapy in a neoadjuvant 
chemotherapy trial [5]. Although more and more new 
LAPTM4B mechanisms of action have been described, 
several unanswered questions have still remained.
One proposed mechanism of action by which 
LAPTM4B may confer anthracycline resistance is the 
cytosolic retention of the drug, thereby reducing the 
drug-induced DNA damage [16]. A different study pro-
posed that the interaction of LAPTM4B-35 isoform with 
MDR1 could result in increased drug efflux. In addition, 
the activation of the PI3K/AKT signaling pathway by 
LAPTM4B-35 was proposed as anti-apoptotic mechanism 
[17, 18]. Li et al. have found that knockdown of LAPTM4B 
in MDA-MB-231 and BT549 cell lines has lead to elevated 
nuclear localization of doxorubicin [5]. Moreover, Li et al. 
found that LAPTM4B is required for lysosome homeo-
stasis, acidification, and function. By limiting lysosome-
mediated cell death and promoting autophagy, the protein 
has a significant effect on cancer cell survival, including 
greater resistance to nutrient deprivation, hypoxia, or 
chemotherapy-induced genotoxic stress [9].
Based on the results obtained from the analysis of our 
neoadjuvant cohort treated with anthracycline-based chem-
otherapy, and documenting higher average LAPTM4B copy 
number in the non-responder group and in pPR responders 
where > 50% of tumor cellularity remains evident, it seems 
reasonable to consider that LAPTM4B may contribute to 
chemoresistance against anthracyclines. In accordance 
with the results of Li et al. [5], we found that LAPTM4B 
alterations were not associated with treatment response 
Fig. 3  Kaplan–Meier curve estimation of DMFS in the anthracy-
cline (AC)-treated adjuvant cohort. Cut-off value for poor progno-
sis was defined as follows: the ratio of amplified cell (LAPTM4B/
CEN8q ≥ 2.0) population is more than 15% and the average gene copy 
number is more than 2.5 per sample. Based on this criterion, 6/22 
cases presented higher LAPTM4B gene copy number, whereas, in 
16/22 cases, lower LAPTM4B gene copy number was detected (log-
rank test, p value was 0.037)
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in the non-anthracycline-treated group of patients. How-
ever, the association of LAPTM4B overexpression with 
tumor progression is more speculative, and there is only 
a limited amount of supporting information in this regard 
[17, 19, 20]. In the present series of HR− breast carcino-
mas, we observed that, in the anthracycline-treated adju-
vant cohort, the average gene copy number was higher in 
primary breast carcinomas where distant metastases were 
diagnosed during the follow-up period compared to the 
non-metastatic ones. It is questionable whether the asso-
ciation of LAPTM4B with poor prognosis is a consequence 
of anthracycline resistance or, as it is presented by Xiao 
M. et al., LAPTM4B has other mechanisms of action to 
promote cell proliferation, migration, invasion, leading to 
simultaneous upregulation of N-cadherin, vimentin, and 
downregulation of E-cadherin in T47D cells [20].
Li et  al. found that elevated level of LAPTM4B and 
YWHAZ (another gene localized on 8q22) mRNAs was 
associated with shorter DMFS in women treated with adju-
vant anthracycline chemotherapy. They also questioned 
whether this is a prognostic effect or a role of this two genes 
in chemotherapy resistance [5]. In other tumor types, such 
as hepatocellular- and ovarian carcinomas, the prognostic 
role of LAPTM4B was documented [21, 22]. Although Xiao 
M et al. showed that high LAPTM4B expression level is 
an independent predictor of axillary lymph node metastasis 
in breast carcinoma patients, unfortunately, no data were 
presented related to different breast cancer subtypes. In our 
study, only HR− breast carcinomas were analyzed and we 
found no significant difference of LAPTM4B copy number 
between HER2 + and TNBC subtypes. However, further 
analysis may be needed using higher number of cases.
The prognostic value of higher average CEN8q or chro-
mosome 8 polysomy in breast carcinomas is not clear. We 
have found significantly higher average CEN8q copies in the 
group of patients with inferior response to anthracycline-
based neoadjuvant therapy. Anna Batistatou et al. in 2017 
have found that polysomy-8 was present in 39% HER2-
positive tumors and in 30.2% HER2-negative tumors. They 
also showed that MYC gene amplification in the presence 
of chromosome-8 instability has distinct effects on patient 
outcome compared with MYC amplification with intact 
CEN8 [23].
In summary, the results of our study confirm the pos-
sible role of LAPTM4B gene in anthracycline resistance 
in HR− breast carcinomas. Alternative treatment modali-
ties without anthracycline should be considered for those 
patients whose cancer harbors extra copies LAPTM4B.
Limitations of the study
Our results should be interpreted cautiously, since our 
patient cohort had relatively few cases in the pNR group. 
Cases were retrospectively selected from prospectively 
maintained databases.
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